• CVD REAL: Primary Prevention for SGLT-2 Inhibitors in Diabetes?

    One year ago - By Medscape

    The CVD REAL study hints that patients with diabetes, even without existing cardiovascular disease, could benefit from this drug class, but some question the survival benefit seen in such a brief time.
    Medscape Medical News
    Read more ...